Jane Street Group LLC Has $344,000 Position in MEDNAX Inc (MD)

Jane Street Group LLC lessened its position in MEDNAX Inc (NYSE:MD) by 79.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 7,979 shares of the company’s stock after selling 30,893 shares during the quarter. Jane Street Group LLC’s holdings in MEDNAX were worth $344,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. QS Investors LLC lifted its position in MEDNAX by 0.3% during the second quarter. QS Investors LLC now owns 3,812 shares of the company’s stock worth $230,000 after buying an additional 12 shares in the last quarter. Pacer Advisors Inc. lifted its position in MEDNAX by 8.1% during the second quarter. Pacer Advisors Inc. now owns 1,940 shares of the company’s stock worth $117,000 after buying an additional 145 shares in the last quarter. Commonwealth Bank of Australia lifted its position in MEDNAX by 15.3% during the second quarter. Commonwealth Bank of Australia now owns 2,205 shares of the company’s stock worth $132,000 after buying an additional 293 shares in the last quarter. GHP Investment Advisors Inc. lifted its position in MEDNAX by 6.0% during the second quarter. GHP Investment Advisors Inc. now owns 7,475 shares of the company’s stock worth $451,000 after buying an additional 420 shares in the last quarter. Finally, Thrivent Financial For Lutherans lifted its position in MEDNAX by 5.5% during the second quarter. Thrivent Financial For Lutherans now owns 18,730 shares of the company’s stock worth $1,131,000 after buying an additional 970 shares in the last quarter. Institutional investors and hedge funds own 98.43% of the company’s stock.

In other news, insider John C. Pepia sold 3,000 shares of MEDNAX stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $51.58, for a total value of $154,740.00. Following the completion of the sale, the insider now directly owns 35,569 shares of the company’s stock, valued at $1,834,649.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Cesar L. Alvarez sold 10,668 shares of MEDNAX stock in a transaction on Friday, November 3rd. The shares were sold at an average price of $42.59, for a total value of $454,350.12. Following the completion of the sale, the director now directly owns 44,215 shares of the company’s stock, valued at $1,883,116.85. The disclosure for this sale can be found here. Insiders own 2.40% of the company’s stock.

A number of equities analysts recently commented on the company. Jefferies Group reiterated a “hold” rating and set a $46.00 price objective on shares of MEDNAX in a research report on Tuesday, October 3rd. SunTrust Banks set a $55.00 price objective on MEDNAX and gave the stock a “hold” rating in a research report on Thursday, December 21st. Citigroup reduced their target price on MEDNAX from $52.00 to $47.00 and set a “neutral” rating on the stock in a research report on Friday, November 3rd. Zacks Investment Research upgraded MEDNAX from a “sell” rating to a “hold” rating in a research report on Wednesday, October 11th. Finally, Robert W. Baird lifted their target price on MEDNAX from $47.00 to $48.00 and gave the company a “neutral” rating in a research report on Friday, November 3rd. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and three have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $53.82.

MEDNAX Inc (MD) traded up $0.75 during trading hours on Thursday, reaching $54.17. The company’s stock had a trading volume of 657,063 shares, compared to its average volume of 1,310,000. MEDNAX Inc has a 12 month low of $40.56 and a 12 month high of $72.13. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.37 and a quick ratio of 1.37. The stock has a market capitalization of $5,070.00, a P/E ratio of 19.21, a P/E/G ratio of 1.64 and a beta of 0.39.

MEDNAX (NYSE:MD) last posted its earnings results on Wednesday, November 1st. The company reported $0.87 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.87. MEDNAX had a return on equity of 10.80% and a net margin of 7.76%. The company had revenue of $868.95 million for the quarter, compared to the consensus estimate of $864.78 million. During the same quarter in the previous year, the business earned $1.09 earnings per share. The company’s revenue for the quarter was up 4.9% on a year-over-year basis. equities analysts expect that MEDNAX Inc will post 3.1 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This story was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at https://stocknewstimes.com/2018/01/11/jane-street-group-llc-has-344000-holdings-in-mednax-inc-md.html.

About MEDNAX

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Institutional Ownership by Quarter for MEDNAX (NYSE:MD)

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply